MEAD JOHNSON/BRISTOL LABS CONSOLIDATION WILL BE HEADED BY RAYMOND EGAN
MEAD JOHNSON/BRISTOL LABS CONSOLIDATION WILL BE HEADED BY RAYMOND EGAN effective Jan. 2, 1986, Bristol-Myers announced in a Sept. 25 press release. The newly created Bristol-Myers U.S. Pharmaceutical Group will "consolidate the functions of manufacturing, engineering, materials management, finance computed services and personnel under the Bristol-Myers U.S. Pharmaceutical & Nutritional Group" the release stated. Raymond Egan, 42, currently president of Mead Johnson, was named exec VP of the U.S. Pharmaceutical & Nutritional Group, the release noted. He began his career with the company in 1968 as a marketing research analyst with Bristol Labs, holding a series of other positions with that division before becoming VP of marketing. In 1982 he moved to Mead Johnson as exec VP and was named president in 1984. According to the company, the existing pharmaceutical business units of Bristol Labs and Mead Johnson -- Bristol Labs Pharmaceutical Division, Bristol-Myers Oncology Division, Mead Johnson Pharmaceutical Division and Mead Johnson Labs Division -- will become divisions of the newly created group. The new U.S. Pharmaceutical Group, the Mead Johnson Nutritional Group, the Bristol Labs Animal Health Care Division and Westwood Pharmaceuticals will comprise the U.S. Pharmaceutical & Nutritional Group, the release noted. The consolidation moves are being made "to provide a more flexible organization able to seize both near and longer term opportunities presented by emerging changes in the cosmetic health care system," said U.S. Pharmaceuticals & Nutritional Group President Wayne Davidson. "Over the past year it has become increasingly clear that the U.S. health care delivery system is in the process of a fundamental restructuring. As these changes occur, the drug selection process also changes." Bristol Labs products falling under Egan's new responsibilities include: cancer drugs VePesid, Platinol, Mytamycin and Blenoxane; antibiotics Ultracef, Precef, Amikin and Cefadyl; the analgesic Stadol; and the Naldecon line of cold products. Mead Johnson pharmaceutical products include: the oral cephalosporin Durice the antidepressant Desyrel; Puestran, a cholesterol-lowering agent; Ovcon oral contraceptives; K-Lyte and Klotrix potassium supplements; and anticonstipants Colace and Peri-Colace.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth